Literature DB >> 11000062

Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer.

S G Ayre, D P Garcia y Bellon, D P Garcia.   

Abstract

The endogenous molecular biology of cancer cells involves autocrine and paracrine secretion of insulin and insulin-like growth-factors I and II, which subserve energy production and growth stimulation, respectively, in these cells. These activities confer on cancer its malignant potential, working as they do autonomously, free from higher levels of integrated control. Taking advantage of cancer's mechanisms of malignancy by employing exogenous insulin as a biologic response modifier, it is possible to potentiate the cytotoxic effects of chemotherapeutic agents for improved treatment of cancer. A synergy between certain membrane and metabolic effects of insulin on cancer cell molecular biology increases anticancer drug efficacy, and it does so with reduced doses of the drugs, enhancing their safety. This treatment strategy has been applied abroad over the last five decades with very promising clinical results. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000062     DOI: 10.1054/mehy.2000.1063

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  5 in total

1.  Insulin in endometrial carcinoma chemotherapy: a beneficial addition and not a problem.

Authors:  Huilan Sha; Yanhui Li; Xuan Du; Hongbo Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

2.  Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer.

Authors:  Christo Damyanov; Desislava Gerasimova; Ivan Maslev; Veselin Gavrilov
Journal:  ISRN Urol       Date:  2012-05-08

3.  Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.

Authors:  Ekaterina Volkova; Bridget A Robinson; Jinny Willis; Margaret J Currie; Gabi U Dachs
Journal:  Oncol Lett       Date:  2013-11-27       Impact factor: 2.967

Review 4.  Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.

Authors:  R J Klement; M K Fink
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

5.  Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance.

Authors:  Ahmad Aljada; Ayman M Saleh; Salem Al Suwaidan
Journal:  Diagn Pathol       Date:  2014-05-22       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.